Price

US$ 17,10

variation (12m)

-2,06% Logo

p/l

20,53

p/vp

10,77

DIVIDEND YIELD

0,00%
graph

quote ADMA

BVMF
ADMA
If you had invested
If you had invested
year ago
year ago
6 months
1 year
5 years
10 years
today you would have
today you would have:
*The figure considers the reinvestment of dividends.

profitability of ADMA

1 month
3 months
1 year
2 years
5 years
10 years
profitability
1 month
-5,05%
3 months
-12,35%
1 year
-2,06%
2 years
332,91%
5 years
0,00%
10 years
0,00%

real profitability

profitability minus inflation.

1 month
-5,05%
3 months
-12,79%
1 year
-6,94%
2 years
294,61%
5 years
0,00%
10 years
0,00%
Estatistica

Indicators ADMA

check out the fundamentals of ADMA Biologics shares

P/L

20,53
Sector: -3,27 Industry: -3,27

P/SALES (PSR)

9,05
Sector: -3,77 Industry: -3,77

P/VP

10,77
Sector: 1,74 Industry: 1,74

DIVIDEND YIELD (DY)

0,00%
Sector: - Industry: -

ROA

37,42%
Sector: -63,50% Industry: -63,50%

ROE

52,45%
Sector: -67,23% Industry: -67,23%

ROIC

36,49%
Sector: -2.087,74% Industry: -2.087,74%

Net Margin

44,06%
Sector: -43,34% Industry: -43,34%

GROSS MARGIN

53,00%
Sector: 40,50% Industry: 40,50%

OPERATING MARGIN

32,82%
Sector: -43,21% Industry: -43,21%

P/EBITDA

26,61
Sector: -3,13 Industry: -3,13

P/EBIT

27,64
Sector: -3,41 Industry: -3,41

P/ASSETS

7,68
Sector: 1,29 Industry: 1,29

VPA

1,65
Sector: 1,80 Industry: 1,80

LPA

0,87
Sector: -2,09 Industry: -2,09

EQUITY / ASSETS

0,71
Sector: 0,42 Industry: 0,42

CAGR REVENUES 5 YEARS

62,21%
Sector: - Industry: -

CAGR PROFITS 5 YEARS

0,00%
Sector: - Industry: -
RETORNO DO INVESTIMENTO

FAIR PRICE OF ADMA Biologics ASSETS ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Price

The Fair Price formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffet's mentor.

Current price

US$ 17,10

Fair Price

US$ 0,00

Upside Potencial de rentabilidade.

-66,76%
Because it considers equity value in its calculation, the formula does not work well for technology companies.
This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.
statistics

ADMA indicators history

Checklist do Investidor Buy And Hold

Checklist do investidor buy and hold sobre ADMA Biologics

comparator of Stocks

graph

comparison of ADMA with indexes

If you had invested (change) 2 years a year ago, today you would have

R$ 1.000,00 in PETR4 you would have R$ 2.294,60

R$ 1.000,00 in LEVE3 you would have R$ 5.240,60

*The value considers the reinvestment of dividends.
Cotação

dividend history ADMA dividend history

Current DY: 0,00%

5-year average DY: 0,00%

no dividend paid in the period.

ABOUT THE COMPANY

Logo ADMA Biologics

ADMA Biologics Inc.

Average user rating I10

4.0 (13 people)

Estados Unidos

Estados Unidos

21 years

Foundation: 2004

2013

Year of debut on the stock exchange - 12 years

407

Employees

Market value

US$ 4,29 Billions

US$ 4,29 Billions

Net worth

US$ 398,32 Milhões

US$ 398.320.000,00

Assets

US$ 558,38 Milhões

US$ 558.380.000,00

Total Number of Shares

241,00 Milhões

241.000.000

Average Daily Trading Volume

US$ 3,24 Milhões

US$ 3.241.429,86

Sector

Cuidados de saúde

Industry

Biotecnologia

Shares

receitas e lucros

ADMA revenue and profits

graph

PROFIT X PRICE ADMA

resultados

ADMA results

DRAG THE FRAME TO SEE MORE DATA
Resultados

ADMA cash flow

DRAG THE FRAME TO SEE MORE DATA
Ativos e Passivos

evolution of assets - ADMA

Pontos Relevantes

ADMA balance sheet

DRAG THE FRAME TO SEE MORE DATA

Common Questions

What is the price of ADMA Biologics (ADMA) today?

The price of ADMA Biologics (ADMA) today is R$ 92,68, with a variation of -2.06% compared to the last year. The price of ADMA Biologics (ADMA) started the year trading around R$ 92,95 and today it is at R$ 92,68. Follow the real-time price chart, the historical price of ADMA Biologics (ADMA), and stock data from Ibovespa and international markets.

When does ADMA Biologics (ADMA) pay dividends?

ADMA Biologics (ADMA) did not distribute dividends in the last year.

ADMA Biologics (ADMA) is it worth it?

Currently, ADMA Biologics (ADMA) is priced at R$ 92,68, with a P/E of 20,53%, representing a deviation of -1,78% from its historical average P/E. In the last year, the stock showed a variation of -2.06% in its price and distributed R$ 0,00 in dividends, resulting in a Dividend Yield of 0,00%. The total shareholder return was -2,06%.

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How to buy shares of ADMA Biologics (ADMA)?

Investing in shares of ADMA Biologics (ADMA) can be done in two ways: by buying the stock abroad or the BDR in Brazil (if available). The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.

The BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much do 100 shares of ADMA Biologics (ADMA) yield today?

The yield of ADMA Biologics (ADMA) was -5,05% in the last month, -2,06% in the last year and 0,00% in the last 5 years (already considering appreciation and dividends).

In the last 12 months, the company paid a total of R$ 0,00 in dividends, um Dividend Yield de 0,00%.

If you wanted to buy 100 shares of ADMA Biologics (ADMA) today, the total investment would be based on the current price of R$ 92,68.

If past performance were to repeat, the return on your investment would be:

  • In 1 year: R$ 9.077,28
  • In 5 years: R$ 9.268,20
  • In 10 years: 9.268,20

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.